[Pubmed] Low vaccine coverage and absence of exacerbations after vaccination in a Myasthenia Gravis cohort: An observati

[RSS-Bot]

Med Clin (Barc). 2025 Apr 10;164(12):106914. doi: 10.1016/j.medcli.2025.106914. Online ahead of print.

ABSTRACT

INTRODUCTION: This study aims to collect data on the vaccination status of Myasthenia Gravis (MG) patients, assess the coverage of vaccines, and examine MG exacerbations.

METHODS: We conducted a retrospectively observational study including patients diagnosed with MG between 2015 and 2023 with antibodies against acetylcholine receptors.

RESULTS: Eighty-nine patients were analysed. Forty-one (46.1%) were women. The median age at onset was 68 years. The median follow-up was 3.9 years. Sixteen (17.9%) patients had early-onset MG and 32 (36.0%) had ocular MG. Fifty-four (60.7%) patients received pneumococcal vaccines. Seventy-five (84.3%) patients received one dose of the seasonal influenza vaccine. Ten patients (76.9%) received hepatitis A virus (HAV) vaccination, and 33 (64.7%) received four doses of the hepatitis B virus (HBV) vaccine. One and six patients were classified as non-responders for HAV and HBV vaccines, respectively. Two patients were vaccinated with the live attenuated varicella-zoster virus vaccine. No differences were found between vaccination in early versus late-onset MG. No MG exacerbations were observed following vaccination.

DISCUSSION: It is mandatory to establish recommendations for vaccination to ensure timely and appropriate immunisation.

PMID:40215715 | DOI:10.1016/j.medcli.2025.106914


Source: https://pubmed.ncbi.nlm.nih.gov/4021571 ... t9+e462414